Table 2 Comparison between PsA patients and controls at baseline

Women, n(%)

25 (64.1)

29 (74.4)

0.462

Men, n(%)

14 (35.9)

10 (25.6)

Age years

55 (48–62)

56 (48–60)

0.617

Body weight kg

106.0 (93.5–112.5

107.0 (96.5–122.2)

0.358

Body height cm

168.0 (161.0–176.0)

165.0 (161.0–170.0)

0.180

BMI kg/m²

35.2 (33.9–37.9)

38.5 (36.9–41.7)

< 0.001

Waistline cm

115.0 (112.0–122.0)

117.0 (107–126.5)

0.635

BP systolic mmHg

127.5 (115.0–136.0)

122.0 (115.0–137.0)

0.503

BP diastol mmHg

77.5 (70.0–82.5)

77.0 (70.0–85.0)

0.736

CRP mg/L

5 (3–9)

4 (2–6)

0.137

Hb g/L

144 (131–150)

141 (135–149)

0.881

WBC 10⁹/L

6.1 (5.3–7.7)

6.6 (5.6–7.6)

0.719

PLT 10⁹/L

270 (202–299)

266 (225–302)

0.924

S-TC mmol/L

5.5 (4.6–6.2)

4.9 (4.1–5.6)

0.034

S-LDL mmol/L

3.6 (3.0–4.4)

3.2 (2.54.0)

0.08

S- HDL mmol/L

1.4 (1.1–1.6)

1.4 (1.0–1.6)

0.867

S- TG mmol/L

1.6 (1.2–2.4)

1.7 (1.2–2.1)

0.512

HbA1c mmol/mol

35.5 (32.0–37.2)

37.5 (35.0–44.0)

0.003

S-glucose mmol/L

5.7 (5.3–6.2)

6.2 (5.8–7.1)

0.003

Creatinine μmol/L

75 (64–84)

68 (62–79)

0.240

S-urate μmol/L

330 (280–400)

350 (283–384)

0.928

ALT μkat/L

0.52 (0.41–0.68)

0.50 (0.42–0.68)

0.806

Anti-hypertensives, n (%)

17 (43.6)

16 (41.0)

0.819

Lipid lowering therapy n (%)

6 (15.4)

11 (28.2)

0.170

Oral anti-diabetics n (%)

1 (2.6)

4 (10.3)

0.358

Insulin n (%)

0 (0)

1 (2.6)

1.00

Allopurinol, n (%)

2 (5.1)

1 (2.6)

1.00

Mets n (%)

30 (76.9)

28 (71.8)

0.614